Corticoid induced osteoporosis in thrombocytopenic purpura
a case report
Keywords:
Corticosteroid-induced osteoporosis, bisphosphonates, thrombocytopenic purpuraAbstract
Immune Thrombocytopenic Purpura is a blood disorder that causes reduced survival and decreased platelet production and is treated with corticosteroids as the first option. Glucocorticoids have complex effects on bone metabolism, reducing bone matrix formation and contributing to the development of osteoporosis. Bisphosphonates, such as pamidronate, are used in the treatment of osteoporosis and other bone conditions, demonstrating efficacy in inhibiting bone resorption. The objective is to investigate the effects of corticosteroid-induced osteoporosis in a case study, evaluating bone mineral density, risk factors and possible prevention and treatment measures. This case report describes a 78-year-old woman with secondary osteoporosis caused by prolonged use of corticosteroids to treat idiopathic thrombocytopenic purpura. Corticosteroids are effective in treating purpura but can lead to osteoporosis due to negative effects on bone metabolism. The patient received treatment with bisphosphonate, which is effective in reducing the risk of fractures. Bone densitometry showed an improvement in bone density after treatment, although osteopenia was still present. The report highlights the importance of adequate monitoring and treatment of osteoporosis in patients receiving corticosteroids, with the use of bisphosphonates playing a crucial role in the prevention and treatment of the disease
References
Yamasaki S. Bisphosphonate use for glucocorticoid- -induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective. Annals of hematology, 2023. 102(7): 1645-56.
Ferreira Júnior DB, et al. Biometric, histomorphometric, and biochemical profile in atorvastatin calcium treatment of female rats with dexamethasone - induced osteoporosis, Revista Brasilieira de Ortopedia, 2019. 53(5):607-13.
Chen H, et al. High risk of osteoporosis and fracture following solid organ transplantation: a population- -based study. Frontiers in Endocrinology, 2023. 14(11): 67-74.
Lv X, et al. Matrix Metalloproteinases in Relation to Bone Mineral Density: A Two-Sample Mendelian Randomization Study. Frontiers in Genetics, 2021. 12:754-95.
Bray GA. Beyond BMI. Nutrients, 2023. 15(10):22-54. doi:10.3390/nu15102254.
Oliveira LG, Carneiro MLRG, Souza MPG, Souza CG, Moraes FB, Camargo FL. Atualização do Tratamento Medicamentoso da Osteoporose. Rev Bras Ortop. 2021; 56(5):550-7.
Jin YZ, et al. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC musculoskeletal disorders. 2019. 20(1):399.
Ebetino FH, et al. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone, 2022. 156: 116-289.
Varenna M, et al. Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study. Therapeutic advances in musculoskeletal disease. 2022. 14:422-74.
Ibanez F, Elvis J, Ruiz DR, Leda L. Púrpura trombocitopénica imunológica trasvacunación contra covid-19. rev. virtual soc parag med int, 2023. 9(1): 113-17.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Goiana Journal of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
